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ABSTRACT
Purpose The contribution of axonal injury to brain
damage after aneurysmal subarachnoid haemorrhage
(aSAH) is unknown. Neurofilament light chain (NF-L),
a component of the axonal cytoskeleton, has been
shown to be elevated in the cerebrospinal fluid of
patients with many types of axonal injury. We
hypothesised that patients with aSAH would have
elevated cerebrospinal fluid (CSF) NF-L levels and sought
to explore the clinical correlates of CSF NF-L dynamics.
Methods Serial ventricular CSF (vCSF) samples were
collected from 35 patients with aSAH for up to 15 days.
vCSF NF-L measurements were determined by
enzyme-linked immunosorbent assay. NF-L levels were
analysed in relation to acute clinical status, radiological
findings and 6-month outcomes.
Results vCSF NF-L concentrations were elevated in all
patients with aSAH. Patients with early cerebral
ischaemia (ECI), defined as a CT hypodense lesion visible
within the first 3 days, had higher acute vCSF NF-L levels
than patients without ECI. These elevated NF-L levels
were similar in patients with ECI associated with
intracranial haemorrhage and ECI associated with
surgical/endovascular complications. vCSF NF-L levels
did not differ as a function of acute clinical status, clinical
vasospasm, delayed cerebral ischaemia or 6-month
Glasgow Outcome Scale.
Conclusions Elevated vCSF NF-L levels may in part
reflect increased injury to axons associated with ECI.
However, our results suggest that axonal injury after
aSAH as reflected by release of NF-L into the CSF may
not play a major role in either secondary adverse events
or long-term clinical outcomes.
Aneurysmal subarachnoid haemorrhage (aSAH) is
a devastating disease associated with long-term
cognitive impairment in nearly 50% of survivors.1
Key factors associated with unfavourable outcome
include older age, poor presenting neurological
condition, extent of aSAH on head CT, intra-
parenchymal haemorrhage, vasospasm and cerebral
infarction.2 Earlier and more reﬁned methods for
recognition of patients at high risk of the secondary
sequelae would permit early and more aggressive
initiation of appropriate therapy, whereas identiﬁ-
cation of patients likely to suffer poor outcomes
would allow for more informed discussions with
family regarding patient prognosis. Aside from
clinical examination and radiographic imaging, no
diagnostic study is currently used for the early
recognition of patients susceptible to ischaemic
secondary events.
In recent years there has been considerable
effort towards identifying biomarkers (ie, cardiac
troponin, S100-B, a-II spectrin) that might prove
useful in assessing brain injury after aSAH3e5;
however, these biomarkers have not been widely
used in clinical practice to date.
Neuroﬁlaments constitute a major component of
the axonal cytoskeleton and are composed of
neuroﬁlament heavy chain (NF-H 190-210 kDa),
neuroﬁlament medium chain (160 kDa), neuroﬁla-
ment light chain (NF-L 68 kDa) and a-internexin
(66 kDa).6 7 Their function is to maintain axonal
structural integrity.8
Neuroﬁlaments are normally restricted to
intracellular compartments. Disruption of axonal
membrane integrity could result in neuroﬁlament
proteins being released into the extracellular space,
from which they may diffuse into the cerebro-
spinal ﬂuid (CSF). As such, neuroﬁlament
subunits are candidate CSF biomarkers of axonal
injury.
Petzold et al9 reported a correlation between CSF
levels of NF-H and outcome in 17 patients with
aSAH. However, they did not specify whether
patients developed secondary insults. More
recently, Lewis et al10 demonstrated that elevated
CSF and blood NF-H levels in patients with aSAH
were associated with poor outcome and that
patients with vasospasm had higher CSF NF-H
levels compared to those without vasospasm,
suggesting that NF-H may be a useful marker of
axonal injury in aSAH.9 11
NF-L may be a complementary marker of axonal
injury because it has been detected in the CSF of
patients with traumatic brain injury, HIV infection
and neurodegenerative disease. It has also been
detected in the lumbar CSF of patients with
aSAH.6 8 12 13 However, no study has investigated
vCSF levels of NF-L after aSAH. The aims of this
study were to examine the relationship between
vCSF NF-L dynamics and relevant clinical
outcomes.
MATERIALS AND METHODS
Patients
The study was approved by the research ethics
committees of the Ospedale Maggiore Policlinico,
Milano and Washington University, Saint Louis.
Thirty-ﬁve patients with aSAH were enrolled
(Supplementary table 1). Written informed consent
was obtained from patients or, in the comatose
patients, from the next of kin. Clinical manage-
ment was performed as previously described14;
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clinical outcome was assessed at 6 months post-injury using
Glasgow outcome scoring system.15
Neuroradiologic monitoring
All patients received a ﬁrst head CTon admission. A second CT
was performed within 48 h after aneurysm treatment to iden-
tify procedural complications, and a later CT was performed
between days 21 and 28 after aSAH for follow-up. Additional
scans were performed in cases of neurological deterioration such
as the loss of one point of the Glasgow Coma Scale motor
component and/or the presence of new focal deﬁcits.
All CTs were reviewed by two investigators blinded to the
clinical history who independently assessed the occurrence of
ischaemic events. Early cerebral ischaemia (ECI) was deﬁned as
a hypodense lesion that was visible on the CT performed within
the ﬁrst 48 h after aneurysm treatment. Delayed cerebral
ischaemia was deﬁned as the appearance of a new hypodense
lesion detectable on the 21- to 28-day follow-up CT that was
not present on the CT performed within 48 h after aneurysm
treatment.
Criteria for evidence of vasospasm
Clinical vasospasm was deﬁned as neurological deterioration
associated with angiographic conﬁrmation of vasospasm,
deﬁned as an arterial diameter narrowing >20% from baseline,
by a neuroradiologist blinded to the clinical history.
CSF sampling
CSF was collected twice daily from an external ventricular drain
in all patients. The median number of samples per patient was
9 (range 1e21). CSF samples were immediately treated with
10 mM ethylenediaminetetraacetic acid and 0.125% polybrene
(Sigma) to prevent admixed blood from clotting. Supernatant
was separated by centrifugation (10 min at 25003g at 218C) and
stored at 808C. Additionally, CSF samples of 13 patients free of
neurological diseases who underwent lumbar puncture as part of
a study protocol at Washington University, Saint Louis, and
Ospedale Maggiore Policlinico, Milano, served as negative
controls. NF-L levels were analysed by enzyme-linked immu-
nosorbent assay. The protocol was adapted from Van Geel et al6;
for details on analysis and assay procedure, please refer to
supplementary materials.
Statistics
NF-L values did not follow normal distributions. Therefore,
ManneWhitney U tests were used to assess the relationship
between NF-L values and clinical outcomes. KruskaleWallis
test followed by Dunn’s multiple comparison test was used to
assess the relationship between NF-L and ECI. The Wilcoxon
signed rank test was used to investigate the relationship
between changes in NF-L values over time and the occurrence of
vasospasm.
RESULTS
All 35 patients with Fisher grade 3e4 aSAH had elevated
acute vCSF NF-L levels (median 643 pg/ml, range 60e2688 pg/
ml). In two of these patients with aSAH, lumbar CSF was
additionally obtained and also found to have elevated NF-L
levels. In contrast, 0 of 13 non-neurological patients (age
range 36e72 years) had detectable lumbar CSF NF-L levels
(<12 pg/ml).
To explore the relationship between vCSF NF-L levels and
initial clinical status after aSAH, we divided the patients into
good (1e3) versus poor (4e5) World Federation of Neurosurgical
Societies (WFNS) grade, as well as good (5e6) versus poor (1e4)
Glasgow Coma Scale motor component. Acute NF-L levels did
not differ between good versus poor initial clinical status groups
(Supplementary ﬁg 1). This indicates that vCSF NF-L levels do
not reﬂect initial injury severity as reﬂected by clinical status.
ECI may cause injury to axons in both grey and white matter.
We found that vCSF NF-L levels were signiﬁcantly higher in
patients with ECI compared to patients without ECI (p<0.01),
although there was considerable overlap between groups
(ﬁgure 1 and Supplementary ﬁg 2). vCSF NF-L levels on days
1e2 were elevated most prominently in patients with ECI
related to intracranial haemorrhage (median 1229 pg/ml, range
93e2688 pg/ml, n¼14 patients, p¼0.01 vs no ECI) but also
elevated in patients with ECI related to complications of aneu-
rysm treatment (median 749 pg/ml, range 100e1678 pg/ml,
n¼8 patients; p¼0.06 vs no ECI). Thus, higher NF-L levels may
reﬂect increased injury to axons associated with ECI.
We next analysed the vCSF NF-L levels in patients who
developed clinically signiﬁcant vasospasm or delayed cerebral
ischaemia. There were no statistically signiﬁcant differences
in vCSF NF-L levels between groups (Supplementary ﬁg 3).
Neither were there changes in vCSF NF-L levels over
time that reﬂected the development of clinical vasospasm
(Supplementary ﬁg 4).
Finally, we assessed whether acute vCSF NF-L levels would be
useful predictors of 6-month clinical outcome. Although there
were trends toward worse outcomes in patients who had the
highest vCSF NF-L levels, there was considerable overlap
between groups and no statistically signiﬁcant differences were
detected (Supplementary ﬁg 5).
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Figure 1 Relationship between vCSF NF-L levels and ECI. The
presence of ECI was associated with higher NF-L levels (KruskaleWallis
test, *p¼0.02). Patients with ECI related to IH showed higher NF-L
levels compared to patients without ECI (p¼0.01, Dunn’s multiple
comparison test). A more modest increase was observed in case of ECI
related to treatment complications (p¼0.06). ECI, early cerebral
ischaemia; IH, intraparenchymal haemorrhage; NF-L, neurofilament light
chain; vCSF, ventricular cerebrospinal fluid.
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DISCUSSION
Our results demonstrate that NF-L, a major component of the
axonal cytoskeleton, can be detected in vCSF as early as 24 h
post-aSAH. The levels of NF-L were higher in patients with CT
evidence of ECI. This occurred in the context of intracranial
haemorrhage or complications of endovascular/surgical aneu-
rysm treatment. However, vCSF NF-L levels were not consis-
tently related to acute clinical status, vasospasm, delayed
cerebral ischaemia and 6-month outcomes.
What underlies the release of NF-L into the vCSF even in
patients without ECI? This has not been determined deﬁni-
tively, but possibilities include axonal shear injury due to a rapid
pressure wave occurring at the time of aneurysm rupture, an
acute rise in intracranial pressure causing mechanical deforma-
tion of axons, transient global ischaemia or ischaemic white
matter injury due to microvascular dysfunction. All of these
would be difﬁcult to detect using current clinical methods. It is
not clear whether vCSF NF-L elevations indicate speciﬁc axonal
injury; more general brain injury processes such as ischaemia
that affect axons indiscriminately along with other brain tissues
appear also to result in NF-L release into the CSF.
An alternative explanation is that the ventricular drain
placement itself was responsible for the high levels of vCSF NF-L
measured. The drain insertion through the brain parenchyma
could release neuroﬁlament from injured axons in the frontal
cortex and white matter.
CONCLUSION
Ventricular CSF NF-L levels are elevated after aSAH. A rela-
tionship between ECI and NF-L levels could be detected
suggesting that NF-L levels may reﬂect increased injury to axons
associated with intracranial haemorrhage and/or surgical or
endovascular complications.
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